SOURCE: CONMED Corporation

CONMED Corporation

April 28, 2011 07:00 ET

CONMED Corporation Announces First Quarter 2011 Financial Results

First Quarter Sales Increase of 4% Driven by 10% Growth in Capital Equipment Revenues

Operating Margin Expansion Helps Generate First Quarter GAAP and Non-GAAP EPS Increases of 24% and 32%, Respectively

Conference Call to Be Held at 10:00 a.m. ET Today

UTICA, NY--(Marketwire - Apr 28, 2011) - CONMED Corporation (NASDAQ: CNMD) today announced financial results for the first quarter of 2011.

Sales for the first quarter ended March 31, 2011 were $183.5 million compared to $176.4 million in the same quarter of 2010, an increase of 4.0%. GAAP diluted earnings per share grew 24.0% to $0.31 compared to $0.25 in the first quarter of 2010. Non-GAAP diluted earnings per share equaled $0.37 compared to non-GAAP diluted earnings per share of $0.28 in the 2010 first quarter, an increase of over 32%. As discussed below under "Use of Non-GAAP Financial Measures," the Company presents various non-GAAP financial measures in this release. Investors should consider non-GAAP measures in addition to, and not as a substitute for, or superior to, financial performance measures prepared in accordance with GAAP. Please refer to the attached reconciliation between GAAP and non-GAAP financial measures.

"We delivered solid top-line growth in the first quarter, and significantly exceeded our bottom-line expectations. With respect to sales, single-use Arthroscopy devices grew 5.8% over the first quarter of 2010, leading the increase in the disposable products category. Capital equipment products, as a whole, grew a robust 10.0% year-over-year. In regards to profitability, of particular note are the increases in operating profit and cash flow resulting from our various efficiency programs. The operating margin percentage increased to 9.4% (10.2% non-GAAP) compared to 7.7% (8.0% non-GAAP) in last year's first quarter. Cash flow was also strong, resulting in meaningful growth in cash and reduction of debt amounting to $18.9 million, which was equivalent to 10.3% of the quarter's revenue," commented Mr. Joseph J. Corasanti, President and Chief Executive Officer.

International sales in the first quarter of 2011 were $91.4 million, representing 49.8% of total sales. Foreign currency exchange rate changes compared to rates in effect in the first quarter of 2010 had a negligible impact on sales.

Cash provided by operations totaled $20.7 million, 2.3 times greater than net income, and was primarily used to reduce debt.

Outlook

Mr. Corasanti added, "We have made consistent measured progress over the last several quarters implementing our strategy for increasing revenues and profitability. New products are gaining traction and cost efficiency actions have grown the bottom-line. While some quarter to quarter fluctuations remain possible given today's ever-evolving business environment, we are clearly trending in the right direction. With respect to the second quarter of 2011, the Company expects revenues of $180 - $185 million and non-GAAP diluted earnings per share of $0.30 - $0.35. Also, we are reiterating our full year 2011 sales guidance of $745 - $755 million, and our non-GAAP earnings per share guidance of $1.40 - $1.50."

The non-GAAP estimates exclude the additional non-cash interest expense on the Company's convertible bonds and restructuring costs expected to be incurred in 2011 related to manufacturing and administrative functions.

The sales and earnings expectations for 2011 are based on the March 2011 currency exchange rates and take into account the currency hedges entered into by the Company. CONMED estimates that 70% of its currency exposure is hedged for 2011.

Restructuring costs

During the first quarter of 2011, the Company continued the consolidation of certain administrative functions and continued the transfer of additional product lines to its Mexican manufacturing facility. Expenses associated with these activities, including severance and relocation costs, amounted to $1.4 million. These charges are included in the GAAP earnings per share set forth above and are excluded from the non-GAAP results. CONMED expects restructuring charges in 2011 to approximate $3.0 - $4.0 million; these costs are excluded from non-GAAP earnings estimates.

Convertible note interest expense

Beginning January 1, 2010, in accordance with guidance issued by the FASB, the Company is now required to record non-cash interest expense related to its convertible notes to bring the effective interest rate to a level approximating that of a non-convertible note of similar size and tenor. In the first quarters of 2011 and 2010, CONMED recorded additional non-cash pre-tax interest charges of $1.1 million in each of those quarters. These charges are included in the GAAP earnings per share set forth above, and excluded from the non-GAAP amounts.

Use of Non-GAAP Financial Measures

Management has disclosed financial measurements in this press announcement that present financial information that is not in accordance with Generally Accepted Accounting Principles ("GAAP"). These measurements are not a substitute for GAAP measurements, although Company management uses these measurements as aids in monitoring the Company's on-going financial performance from quarter-to-quarter and year-to-year on a regular basis, and for benchmarking against other medical technology companies. Non-GAAP net income, non-GAAP earnings per share and non-GAAP operating margin measure the profitability of the Company excluding unusual credits or charges that are considered by management to be outside of the normal on-going operations of the Company. Adjusted Cash Flow Provided by Operating Activities and Cash Flow from Financing Activities are presented to disclose the effect of a change in accounting. Management uses and presents non-GAAP net income, non-GAAP earnings per share and non-GAAP operating margin because management believes that in order to properly understand the Company's short and long-term financial trends, the impact of unusual items should be eliminated from on-going operating activities. These adjustments for unusual items are derived from facts and circumstances that vary in frequency and impact on the Company's results of operations. Management uses non-GAAP net income, non-GAAP earnings per share and non-GAAP operating margin to forecast and evaluate the operational performance of the Company as well as to compare results of current periods to prior periods on a consistent basis. Non-GAAP financial measures used by the Company may be calculated differently from, and therefore may not be comparable to, similarly titled measures used by other companies. Investors should consider non-GAAP measures in addition to, and not as a substitute for, or superior to, financial performance measures prepared in accordance with GAAP.

Conference call

The Company will webcast its first quarter 2011 conference call live over the Internet at 10:00 a.m. Eastern Time on Thursday, April 28, 2011. This webcast can be accessed from CONMED's web site at www.conmed.com. Replays of the call will be made available through May 6, 2011.

CONMED Profile

CONMED is a medical technology company with an emphasis on surgical devices and equipment for minimally invasive procedures and patient monitoring. The Company's products serve the clinical areas of arthroscopy, powered surgical instruments, electrosurgery, cardiac monitoring disposables, endosurgery and endoscopic technologies. They are used by surgeons and physicians in a variety of specialties including orthopedics, general surgery, gynecology, neurosurgery and gastroenterology. Headquartered in Utica, New York, the Company's 3,300 employees distribute its products worldwide from several manufacturing locations.

Forward-Looking Information

This press release contains forward-looking statements based on certain assumptions and contingencies that involve risks and uncertainties. The forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and relate to the Company's performance on a going-forward basis. The forward-looking statements in this press release involve risks and uncertainties which could cause actual results, performance or trends, to differ materially from those expressed in the forward-looking statements herein or in previous disclosures. The Company believes that all forward-looking statements made by it have a reasonable basis, but there can be no assurance that management's expectations, beliefs or projections as expressed in the forward-looking statements will actually occur or prove to be correct. In addition to general industry and economic conditions, factors that could cause actual results to differ materially from those discussed in the forward-looking statements in this press release include, but are not limited to: (i) the failure of any one or more of the assumptions stated above, to prove to be correct; (ii) the risks relating to forward-looking statements discussed in the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2010; (iii) cyclical purchasing patterns from customers, end-users and dealers; (iv) timely release of new products, and acceptance of such new products by the market; (v) the introduction of new products by competitors and other competitive responses; (vi) the possibility that any new acquisition or other transaction may require the Company to reconsider its financial assumptions and goals/targets; and/or (vii) the Company's ability to devise and execute strategies to respond to market conditions.

                            CONMED CORPORATION
                     CONSOLIDATED STATEMENTS OF INCOME
                Three Months Ended March 31, 2010 and 2011
                  (In thousands except per share amounts)
                                (unaudited)

                                                      2010           2011
                                                    --------       --------

Net sales                                           $176,365       $183,450
                                                    --------       --------

Cost of sales                                         84,003         86,980
Cost of sales, other - Note A                            567            754
                                                    --------       --------

Gross profit                                          91,795         95,716
                                                    --------       --------

Selling and administrative                            70,552         70,078
Research and development                               7,682          7,681
Other expense - Note B                                     -            694
                                                    --------       --------
                                                      78,234         78,453
                                                    --------       --------

Income from operations                                13,561         17,263

Amortization of debt discount                          1,052          1,094

Interest expense                                       1,749          1,805
                                                    --------       --------

Income before income taxes                            10,760         14,364

Provision for income taxes                             3,441          5,369
                                                    --------       --------

Net income                                          $  7,319       $  8,995
                                                    ========       ========

Per share data:
    Net income
          Basic                                     $    .25       $    .32
          Diluted                                        .25            .31

    Weighted average common shares
          Basic                                       29,165         28,261
          Diluted                                     29,409         28,701


Note A -Included in cost of sales, other in the three months ended March
31, 2010 and 2011, are $0.6 million and $0.8 million, respectively, related
to the moving of additional product lines to the manufacturing facility in
Chihuahua, Mexico.

Note B - Included in other expense in the three months ended March 31, 2011
are $0.7 million in severance charges related to the consolidation of
administrative functions.




                            CONMED CORPORATION
                  CONSOLIDATED CONDENSED BALANCE SHEETS
                               (in thousands)
                                (unaudited)
                                  ASSETS

                                                   December 31,  March 31,
                                                       2010        2011
                                                    ----------  ----------

Current assets:
        Cash and cash equivalents                   $   12,417  $   17,939
        Accounts receivable, net                       145,350     147,263
        Inventories                                    172,796     171,211
        Deferred income taxes                            8,476       8,874
        Other current assets                            11,153      12,730
                                                    ----------  ----------
                Total current assets                   350,192     358,017

Property, plant and equipment, net                     140,895     141,121
Deferred income taxes                                    2,009       2,333
Goodwill                                               295,068     294,924
Other intangible assets, net                           190,091     188,432
Other assets                                             7,518       7,576
                                                    ----------  ----------
                Total assets                        $  985,773  $  992,403
                                                    ==========  ==========

                   LIABILITIES AND SHAREHOLDERS' EQUITY

Current liabilities:
        Current portion of long-term debt           $  110,433  $  111,528
        Other current liabilities                       69,433      68,977
                                                    ----------  ----------
                Total current liabilities              179,866     180,505

Long-term debt                                          85,182      71,844
Deferred income taxes                                  106,046     110,651
Other long-term liabilities                             28,116      28,359
                                                    ----------  ----------
                Total liabilities                      399,210     391,359
                                                    ----------  ----------

Shareholders' equity:
   Capital accounts                                    248,404     251,191
   Retained earnings                                   354,020     362,685
   Accumulated other comprehensive loss                (15,861)    (12,832)
                                                    ----------  ----------
                Total equity                           586,563     601,044
                                                    ----------  ----------

                Total liabilities and
                 shareholders' equity               $  985,773  $  992,403
                                                    ==========  ==========




                            CONMED CORPORATION
              CONSOLIDATED CONDENSED STATEMENT OF CASH FLOWS
                              (in thousands)
                                (unaudited)

                                                        Three months ended
                                                            March 31,
                                                        ------------------
                                                          2010      2011
                                                        --------  --------
Cash flows from operating activities:
 Net income                                             $  7,319  $  8,995
  Adjustments to reconcile net income to net cash
   provided by operating activities:
 Depreciation and amortization                            10,282    10,340
 Stock-based compensation                                    940     1,026
 Deferred income taxes                                     3,598     4,625
 Sale of accounts receivable to (collections for)
  purchaser                                              (29,000)        -
   Increase (decrease) in cash flows from changes
    in assets and liabilities:
      Accounts receivable                                  5,378        90
      Inventories                                         (8,002)      420
      Accounts payable                                     3,836     1,782
      Income taxes payable                                  (620)      333
      Accrued compensation and benefits                   (3,509)   (7,442)
      Other assets                                          (865)   (1,917)
      Other liabilities                                   (2,289)    2,448
                                                        --------  --------
  Net cash provided by (used in) operating activities    (12,932)   20,700
                                                        --------  --------

Cash flow from investing activities:
      Purchases of property, plant and equipment          (3,333)   (4,143)
      Payments related to business acquisitions           (5,083)      (72)
                                                        --------  --------
  Net cash used in investing activities                   (8,416)   (4,215)
                                                        --------  --------

Cash flow from financing activities:
      Payments on debt                                    (9,337)  (13,337)
      Proceeds from secured borrowings, net               33,000         -
      Net proceeds from common stock issued under
       employee plans                                        267     1,287
      Other, net                                          (2,531)      337
                                                        --------  --------
  Net cash provided by (used in) financing activities     21,399   (11,713)
                                                        --------  --------

Effect of exchange rate change
 on cash and cash equivalents                               (179)      750
                                                        --------  --------

Net increase (decrease) in cash and cash equivalents        (128)    5,522

Cash and cash equivalents at beginning of period          10,098    12,417
                                                        --------  --------

Cash and cash equivalents at end of period              $  9,970  $ 17,939
                                                        ========  ========




                            CONMED CORPORATION
       RECONCILIATION OF REPORTED NET INCOME TO NON-GAAP NET INCOME
          BEFORE UNUSUAL ITEMS AND AMORTIZATION OF DEBT DISCOUNT
                Three Months Ended March 31, 2010 and 2011
                 (In thousands except per share amounts)
                                (unaudited)

                                                          2010     2011
                                                        --------  --------

Reported net income                                   $  7,319    $  8,995
                                                        --------  --------

New plant / facility consolidation costs included in
 cost of sales                                               567       754

Administrative consolidation costs included in other
 expense                                                      -        694

Amortization of debt discount                              1,052     1,094
                                                        --------  --------

Unusual expense before income taxes                       1,619      2,542

Provision (benefit) for income taxes on unusual
 expenses                                                 (593)       (926)
                                                      --------    --------

Net income before unusual items                       $  8,345    $ 10,611
                                                      ========    ========

Per share data:

Reported net income
          Basic                                       $  0.25     $   0.32
          Diluted                                        0.25         0.31

Net income before unusual items
          Basic                                       $  0.29     $   0.38
          Diluted                                        0.28         0.37

Management has provided the above reconciliation of net income before unusual items and amortization of debt discount as an additional measure that investors can use to compare operating performance between reporting periods. Management believes this reconciliation provides a useful presentation of operating performance as discussed in the section "Use of Non-GAAP Financial Measures" above. We have included the amortization of debt discount in our analysis in order to facilitate comparison with the non-GAAP earnings guidance provided in the "Outlook" section of this and previous releases which exclude such expense.

                            CONMED CORPORATION
         IMPACT TO STATEMENT OF CASH FLOWS RELATED TO ACCOUNTING
                       CHANGE APPLIED PROSPECTIVELY
                Three Months Ended March 31, 2010 and 2011
                              (In thousands)
                                (unaudited)

                                                       2010        2011
                                                     ---------   ---------
Reported cash flow from operations                   $ (12,932)  $  20,700
                                                     ---------   ---------

Sale of accounts receivable to (collections for)
 purchaser accounting change and termination of
 facility                                               29,000           -
                                                     ---------   ---------

Adjusted cash flow from operations                   $  16,068   $  20,700
                                                     =========   =========




Reported cash flow from financing activities         $  21,399   $ (11,713)
                                                     ---------   ---------

Proceeds of secured borrowings, net                    (33,000)          -
                                                     ---------   ---------

Adjusted cash flow provided (used) by financing
 activities                                          $ (11,601)  $ (11,713)
                                                     =========   =========



                            CONMED CORPORATION
          RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL MEASURES
               Three Months Ended March 31, 2010 and 2011
                              (In thousands)
                                (unaudited)


Reported income from operations                        $ 13,561   $ 17,263
                                                       --------   --------

New plant/facility consolidation costs included in cost
 of sales                                                   567        754

Administrative consolidation costs included in other
 expense                                                      -        694
                                                       --------   --------

Adjusted income from operations                        $ 14,128   $ 18,711
                                                       ========   ========


Operating Margin
        Reported (GAAP)                                     7.7%       9.4%

        Adjusted (Non-GAAP)                                 8.0%      10.2%

Management has provided the above reconciliations as additional measures that investors can use to compare financial results between reporting periods. Management believes these reconciliations provide a useful presentation of financial measures as discussed in the section "Use of Non-GAAP Financial Measures" above.

                            CONMED CORPORATION
                       First Quarter Sales Summary

                                       Three Months Ended March 31,
                                ------------------------------------------
                                                                  Constant
                                                                  Currency
                                  2010       2011       Growth     Growth
                                ---------- ---------- ---------  ---------
                                    (in millions)
Arthroscopy
   Single-use                   $     54.9 $     58.1       5.8%       5.9%
   Capital                            17.3       17.3       0.0%       0.6%
                                ---------- ---------- ---------  ---------
                                      72.2       75.4       4.4%       4.6%
                                ---------- ---------- ---------  ---------

Powered Surgical Instruments
   Single-use                         20.2       20.4       1.0%       1.0%
   Capital                            14.8       17.7      19.6%      19.7%
                                ---------- ---------- ---------  ---------
                                      35.0       38.1       8.9%       8.9%
                                ---------- ---------- ---------  ---------

Electrosurgery
   Single-use                         17.1       16.7      -2.3%      -2.4%
   Capital                             6.0        6.9      15.0%      13.3%
                                ---------- ---------- ---------  ---------
                                      23.1       23.6       2.2%       1.7%
                                ---------- ---------- ---------  ---------

Endoscopic Technologies
   Single-use                         11.8       11.9       0.8%       0.0%
                                ---------- ---------- ---------  ---------

Endosurgery
   Single-use and reposable           17.1       17.9       4.7%       5.3%
                                ---------- ---------- ---------  ---------
Patient Care
   Single-use                         17.2       16.6      -3.5%      -2.9%
                                ---------- ---------- ---------  ---------

Total
   Single-use and reposable          138.3      141.6       2.4%       2.5%
   Capital                            38.1       41.9      10.0%      10.0%
                                ---------- ---------- ---------  ---------
                                $    176.4 $    183.5       4.0%       4.1%
                                ========== ========== =========  =========

Contact Information

  • CONTACT:
    CONMED Corporation
    Robert Shallish
    Chief Financial Officer
    315-624-3206

    FD
    Investors:
    Brian Ritchie
    212-850-5600